Biblio
] , “Tumor-Promoting/Associated Inflammation and the Microenvironment: A State of the Science and New Horizons”, Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018, pp. 473 - 510.
, “Tea catechins inhibit hepatocyte growth factor receptor (MET kinase) activity in human colon cancer cells: kinetic and molecular docking studies”, Journal of medicinal chemistry, vol. 52, pp. 6543–6545, 2009.
, “Tea catechins as inhibitors of receptor tyrosine kinases: mechanistic insights and human relevance”, Pharmacological Research, vol. 62, pp. 457–464, 2010.
, “TCDD, FICZ, and other high affinity AhR ligands dose-dependently determine the fate of CD4+ T cell differentiation.”, Toxicol Sci, 2018.
, “A targeted mass spectrometry-based approach for the identification and characterization of proteins containing $\alpha$-aminoadipic and $\gamma$-glutamic semialdehyde residues”, Analytical and bioanalytical chemistry, vol. 398, pp. 2905–2914, 2010.
, “Synthesis of (R)-4, 4, 4-trifluoro-2-mercaptobutyric acid”, Tetrahedron: Asymmetry, vol. 11, pp. 2125–2131, 2000.
, “Synthesis and biological evaluation of benzo [4, 5] imidazo [1, 2-c] pyrimidine and benzo [4, 5] imidazo [1, 2-a] pyrazine derivatives as anaplastic lymphoma kinase inhibitors”, Bioorganic & medicinal chemistry, vol. 22, pp. 1303–1312, 2014.
, “Synthesis and binding studies of epibatidine analogues as ligands for the nicotinic acetylcholine receptors”, European journal of medicinal chemistry, vol. 41, pp. 640–650, 2006.
, “Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3′, 4′-dimethoxy-$\alpha$-naphthoflavone”, Molecular pharmacology, vol. 79, pp. 508–519, 2011.
, “Structure-activity relationships of the main bioactive constituents of Euodia ruticarpa on aryl hydrocarbon receptor activation and bile acid homeostasis”, Drug Metabolism and Disposition, p. dmd.117.080176, 2018.
, “A Structural Switch between Agonist and Antagonist Bound Conformations for a Ligand-Optimized Model of the Human Aryl Hydrocarbon Receptor Ligand Binding Domain”, Biology, vol. 399, no. 4, pp. 645 - 669, 2014.
, “A structural switch between agonist and antagonist bound conformations for a ligand-optimized model of the human aryl hydrocarbon receptor ligand binding domain”, Biology, vol. 3, pp. 645–669, 2014.
, “A Structural Switch between Agonist and Antagonist Bound Conformations for a Ligand-Optimized Model of the Human Aryl Hydrocarbon Receptor Ligand Binding Domain.”, Biology (Basel), vol. 3, no. 4, pp. 645-69, 2014.
, “Solution Structure, Dimerization, and Dynamics of a Lipophilic $\alpha$/310-Helical, C$\alpha$-Methylated Peptide. Implications for Folding of Membrane Proteins”, Journal of the American Chemical Society, vol. 123, pp. 6678–6686, 2001.
, “Site-specific proteomic analysis of lipoxidation adducts in cardiac mitochondria reveals chemical diversity of 2-alkenal adduction”, Journal of proteomics, vol. 74, pp. 2417–2429, 2011.
, “Self-assembling cannabinomimetics: supramolecular structures of N-alkyl amides”, Journal of natural products, vol. 70, pp. 1010–1015, 2007.
, “The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling”, Carcinogenesis, vol. 36, pp. S38–S60, 2015.
, “Mono-substituted isopropylated triaryl phosphate, a major component of Firemaster 550, is an AHR agonist that exhibits AHR-independent cardiotoxicity in zebrafish.”, Aquat Toxicol, vol. 154, pp. 71-9, 2014.
, “Mono-substituted isopropylated triaryl phosphate, a major component of Firemaster 550, is an AHR agonist that exhibits AHR-independent cardiotoxicity in zebrafish”, Aquatic Toxicology, vol. 154, pp. 71–79, 2014.
, “Mono-substituted isopropylated triaryl phosphate, a major component of Firemaster 550, is an AHR agonist that exhibits AHR-independent cardiotoxicity in zebrafish”, Aquatic Toxicology, vol. 154, pp. 71 - 79, 2014.
, “Molecular basis of agonicity and antagonicity in the androgen receptor studied by molecular dynamics simulations”, Journal of Molecular Graphics and Modelling, vol. 27, no. 4, pp. 452 - 458, 2008.
, “Modeling of the aryl hydrocarbon receptor (AhR) ligand binding domain and its utility in virtual ligand screening to predict new AhR ligands”, Journal of medicinal chemistry, vol. 52, pp. 5635–5641, 2009.
, “Modeling of the Aryl Hydrocarbon Receptor (AhR) Ligand Binding Domain and Its Utility in Virtual Ligand Screening to Predict New AhR Ligands”, Journal of Medicinal Chemistry, vol. 52, no. 18, pp. 5635 - 5641, 2009.
, “Modeling of the aryl hydrocarbon receptor (AhR) ligand binding domain and its utility in virtual ligand screening to predict new AhR ligands.”, J Med Chem, vol. 52, no. 18, pp. 5635-41, 2009.